There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Morphosys Ag (MOR – Research Report) and Monte Rosa Therapeutics (GLUE – Research Report) with bullish sentiments.
Morphosys Ag (MOR)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Morphosys Ag, with a price target of $15.00. The company’s shares closed last Thursday at $4.00, close to its 52-week low of $3.17.
According to TipRanks.com, Butler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Morphosys Ag is a Hold with an average price target of $8.95.
See the top stocks recommended by analysts >>
Monte Rosa Therapeutics (GLUE)
In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Monte Rosa Therapeutics, with a price target of $28.00. The company’s shares closed last Thursday at $6.97, close to its 52-week low of $6.05.
According to TipRanks.com, Shu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monte Rosa Therapeutics with a $22.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MOR:
